Study provides genetic evidence on new osteoporosis drug heart attack risk

by

New research highlights potential safety concerns around women taking romosozumab, a new anti-osteoporosis drug available on the NHS. The University of Bristol-led study, published in Arthritis & Rheumatology, analyzed genetic data on nearly 34,000 people.

Leave A Comment

Your email address will not be published. Required fields are marked *